Holen Sie sich die Stockscreener-App
0.8567
3.90%
-0.0348
Handel nachbörslich:
.84
-0.0167
-1.95%
Schlusskurs vom Vortag:
$0.8915
Offen:
$0.87
24-Stunden-Volumen:
228.98K
Relative Volume:
0.53
Marktkapitalisierung:
$16.76M
Einnahmen:
$411.00K
Nettoeinkommen (Verlust:
$-4.85M
KGV:
-1.947
EPS:
-0.44
Netto-Cashflow:
$-4.88M
1W Leistung:
-2.51%
1M Leistung:
-15.18%
6M Leistung:
-36.07%
1J Leistung:
-72.00%
1-Tages-Spanne:
$0.84
$0.90
1-Wochen-Bereich:
$0.8019
$0.99
52-Wochen-Spanne:
$0.7749
$3.15
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Firmenname
Lexaria Bioscience Corp
Sektor
Branche
Telefon
250-765-6424
Adresse
100 - 740 MCCURDY ROAD, KELOWNA
Vergleichen Sie LEXX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
0.8567 | 19.81M | 411.00K | -4.85M | -4.88M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lexaria Bioscience Corp Aktie (LEXX) Neueste Nachrichten
Earnings visualization tools for Lexaria Bioscience Corp. Equity Warrant2025 Valuation Update & Safe Capital Growth Tips - newser.com
Can trapped investors hope for a rebound in Lexaria Bioscience Corp. Equity WarrantTrade Risk Assessment & Precise Trade Entry Recommendations - newser.com
Will Lexaria Bioscience Corp. Equity Warrant outperform the marketBull Run & Real-Time Volume Spike Alerts - newser.com
Can Lexaria Bioscience Corp. hit a new high this monthMarket Risk Analysis & Smart Allocation Stock Reports - newser.com
Lexaria expands pharmaceutical outreach with new advisory firm By Investing.com - Investing.com Nigeria
Lexaria Bioscience Corp. Provides Strategic Update - NewMediaWire
Lexaria Bioscience Expands Strategic Outreach and Secures New Patents - TipRanks
Lexaria (LEXX) Expands R&D Efforts with Enhanced Funding and New Partnerships - GuruFocus
Lexaria expands pharmaceutical outreach with new advisory firm - Investing.com India
$4.0M Financing backs Lexaria's global BD push; 4 new patents bolster DehydraTECH R&D into 2026 - Stock Titan
Can trapped investors hope for a rebound in Lexaria Bioscience Corp.2025 Major Catalysts & Community Verified Swing Trade Signals - newser.com
Historical volatility pattern of Lexaria Bioscience Corp. visualized2025 Institutional Moves & Fast Momentum Stock Entry Tips - newser.com
Custom watchlist performance reports with Lexaria Bioscience Corp.2025 Major Catalysts & Pattern Based Trade Signal System - newser.com
News impact scoring models applied to Lexaria Bioscience Corp. Equity WarrantMarket Sentiment Report & Real-Time Volume Analysis - newser.com
Can swing trading help recover from Lexaria Bioscience Corp. Equity Warrant losses2025 Key Lessons & Weekly Top Gainers Alerts - newser.com
Lexaria Bioscience Corp Stock Analysis and ForecastAutomated Trading Signals & Explosive Capital Growth - earlytimes.in
Will Lexaria Bioscience Corp. see short term momentumMarket Sentiment Report & Fast Entry High Yield Stock Tips - newser.com
Lexaria Bioscience Corp. Equity Warrant stock daily chart insightsWeekly Risk Report & High Conviction Trade Alerts - newser.com
Real time social sentiment graph for Lexaria Bioscience Corp.Quarterly Trade Review & Technical Pattern Based Buy Signals - newser.com
Smart tools for monitoring Lexaria Bioscience Corp.’s price actionWeekly Market Outlook & Weekly Stock Performance Updates - newser.com
Can Lexaria Bioscience Corp. Equity Warrant stock deliver surprise earnings beatCPI Data & Fast Moving Trade Plans - newser.com
When is the best time to exit Lexaria Bioscience Corp.Entry Point & Community Verified Trade Signals - newser.com
Is Lexaria Bioscience Corp. stock reversal real or fakeAnalyst Downgrade & Reliable Price Action Trade Plans - newser.com
What drives Lexaria Bioscience Corp stock priceFundamental Stock Analysis & High Yield Trading Plans - earlytimes.in
Lexaria Bioscience Corp. Equity Warrant stock trendline breakdownWeekly Stock Summary & Accurate Buy Signal Alerts - newser.com
What’s next for Lexaria Bioscience Corp. Equity Warrant stock price2025 Price Action Summary & Breakout Confirmation Alerts - newser.com
Chart based exit strategy for Lexaria Bioscience Corp. Equity WarrantJuly 2025 Momentum & Free High Return Stock Watch Alerts - newser.com
Will earnings trigger a reversal in Lexaria Bioscience Corp.2025 Stock Rankings & Reliable Trade Execution Plans - newser.com
LEXX: Biodistribution Study Results - Yahoo Finance
Lexaria Bioscience announces ~$4M registered direct offering of shares - MSN
Lexaria Bioscience Ends Capital on Demand Agreement - MSN
Lexaria Bioscience (NASDAQ:LEXX) Trading Down 6.4% – What’s Next? - Defense World
Lexaria Bioscience Secures $4 Million in Capital Funding to Advance 2026 Research Initiatives - citybuzz
Lexaria Bioscience Secures $4 Million for R&D Expansion - TipRanks
Lexaria Bioscience enters securities purchase agreement with investorsSEC filing - TradingView
Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain - StreetInsider
Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Investing News Network
Finanzdaten der Lexaria Bioscience Corp-Aktie (LEXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lexaria Bioscience Corp-Aktie (LEXX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BUNKA CHRISTOPHER | Director |
Jul 30 '25 |
Buy |
0.91 |
11,900 |
10,866 |
281,912 |
| McKechnie William Edward | Director |
Jul 29 '25 |
Buy |
0.91 |
5,000 |
4,532 |
18,191 |
| DOCHERTY JOHN MARTIN | President & CSO |
Jul 29 '25 |
Buy |
0.93 |
5,376 |
4,989 |
5,376 |
| Carle Vanessa | Secretary |
Jul 29 '25 |
Buy |
0.91 |
750 |
682 |
750 |
| CHRISTOPHER RICHARD | Chief Executive Officer |
Jul 29 '25 |
Buy |
0.91 |
15,000 |
13,641 |
65,000 |
| CHRISTOPHER RICHARD | Chief Executive Officer |
Dec 03 '24 |
Buy |
2.47 |
27,172 |
67,175 |
50,000 |
| CHRISTOPHER RICHARD | Chief Executive Officer |
Dec 02 '24 |
Buy |
2.24 |
22,828 |
51,217 |
22,828 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):